DOJ Alleges Yale Medical School Discriminated Against Asian and White Applicants

On May 14, 2026, the Department of Justice announced that a year-long investigation had determined that Yale School of Medicine "intentionally selected applicants based on their race," favoring Black and Hispanic candidates over White and Asian ones with stronger academic credentials [1]. The finding landed just eight days after the DOJ issued a nearly identical determination against UCLA's David Geffen School of Medicine [2], and while an investigation into Ohio State's College of Medicine remains open [3]. Together, the three actions represent the most aggressive federal enforcement campaign against race-conscious admissions in the history of American medical education.

The stakes extend well beyond New Haven. If the DOJ prevails — through a voluntary compliance agreement or, failing that, litigation — the outcome could reshape how every federally funded medical school in the country selects its students, with direct consequences for the racial composition of America's physician workforce.

What the DOJ Found

The Civil Rights Division's investigation examined Yale's admissions data for the incoming classes of 2023, 2024, and 2025, covering admissions decisions made after the Supreme Court's June 2023 ruling in Students for Fair Admissions v. Harvard that banned race-conscious admissions [1][4].

The DOJ's findings center on measurable gaps in the academic profiles of admitted students across racial groups. For Yale's most recent class, the data showed [1][5]:

• Black students: median GPA of 3.88, median MCAT score at the 95th percentile
• White students: median GPA of 3.97, median MCAT score at the 100th percentile
• Asian students: median GPA of 3.98, median MCAT score at the 100th percentile

Source: DOJ Letter of Findings

Data as of May 14, 2026CSV

The most striking statistic in the DOJ's letter of findings concerns interview selection: according to the agency's preliminary analysis of applicant-level data, a Black applicant had "as much as 29 times higher odds of getting an interview for admission than an equally strong Asian applicant with similar academic credentials" [1][6]. The DOJ also alleged that Yale's internal documents showed the school's leadership "studied how to use racial proxies to circumvent" the Supreme Court's prohibition on race-based selection [7].

Assistant Attorney General Harmeet K. Dhillon summarized the findings bluntly: "Yale has continued its race-based admissions program despite the Supreme Court and the public's clear mandate for reform" [7].

Yale's Defense

Yale's initial response was measured. Spokesperson Karen Peart stated that the university is "confident in the rigorous admissions process we follow," adding that "the students admitted to Yale School of Medicine demonstrate exceptional academic achievement and personal commitment" and that graduates "go on to become leaders in clinical care, research, and public service" [5][6]. Yale's attorney, Peter Spivack, did not immediately respond to requests for comment [5].

The university has not yet released a detailed rebuttal addressing the DOJ's statistical methodology. Several possible lines of defense are available. Yale could argue that GPA and MCAT scores, while important, are not the sole measures of applicant quality — that factors like clinical experience, research contributions, personal statements, and letters of recommendation justify the admissions outcomes. It could also contend that the DOJ's analysis fails to account for non-racial variables that correlate with race, including socioeconomic background, first-generation college student status, or geographic origin.

The DOJ's letter does not indicate that its analysis controlled for these variables, a gap that admissions experts have flagged. The statistical method of comparing applicants with "similar academic credentials" without adjusting for socioeconomic class, legacy status, or institutional relationships leaves open the question of whether race itself — or correlated factors — drove the observed disparities.

The Legal Framework: Title VI and Students for Fair Admissions

The DOJ's legal theory rests on Title VI of the Civil Rights Act of 1964, which prohibits discrimination on the basis of race, color, or national origin in any program or activity receiving federal financial assistance [1][7]. Because Yale School of Medicine receives substantial federal funding — through research grants from the National Institutes of Health, Medicare graduate medical education payments, and other federal programs — it is bound by Title VI's requirements.

The Supreme Court's 2023 decision in Students for Fair Admissions v. Harvard declared that race-conscious admissions at Harvard College and the University of North Carolina violated the Equal Protection Clause of the Fourteenth Amendment [4]. The ruling effectively overturned decades of precedent established by Grutter v. Bollinger (2003) and Regents of the University of California v. Bakke (1978), both of which had permitted limited consideration of race in admissions [4].

A critical question is whether the SFFA ruling applies to graduate and professional programs or only to undergraduate admissions. The AAMC has stated that "in addition to undergraduate programs, the ruling applies to admissions for graduate and medical programs" [8]. The DOJ clearly shares this interpretation.

However, the SFFA majority opinion included a notable carve-out: "Nothing in this opinion should be construed as prohibiting universities from considering an applicant's discussion of how race affected his or her life, be it through discrimination, inspiration, or otherwise" [4]. This language creates a boundary that remains contested. The DOJ alleges Yale went well beyond discussing individual experiences — that it used race as a categorical factor in admissions decisions.

A Pattern: UCLA and Beyond

Yale is not the DOJ's first target. On May 6, 2026, the department issued a letter of findings to UCLA's David Geffen School of Medicine alleging substantially similar violations across the same admissions cycles (classes of 2023, 2024, and 2025) [2].

The UCLA findings cited even starker academic disparities. In 2023, Black and Hispanic students admitted to DGSOM had median MCAT scores at the 68th percentile, while all other demographic groups scored at the 86th percentile or higher. In 2024, Black students scored at the 72nd percentile and Hispanic students at the 66th percentile, with other groups again at 86 percent or above [2].

The DOJ has also opened a Title VI investigation into Ohio State University's College of Medicine focused on "possible race discrimination" in admissions [3]. The breadth of these actions — spanning a private Ivy League school, a public University of California campus, and a large state research university — suggests a systematic enforcement strategy rather than isolated complaints.

What the Experts Say

Legal and admissions scholars are divided on the merits of the DOJ's approach.

Julie Park, a professor of education at the University of Maryland and a leading admissions researcher, has argued that the Trump administration's interpretation of SFFA "probably goes well beyond the court's intentions." She stated: "They probably have their vision of what they think compliance with SFFA is, but that's not what SFFA actually says" [9].

Mark Henderson, associate dean for admissions at UC Davis School of Medicine, has raised a related concern — that the DOJ's enforcement posture is causing medical schools to abandon diversity strategies that remain legally permissible. "Admissions officers are being advised by lawyers to go beyond what SCOTUS said," Henderson stated, and he has urged colleagues to "push back on legal advice that may be too restrictive" [9].

On the other side, supporters of the DOJ's action argue that the statistical evidence speaks for itself — that a 29-to-1 odds ratio in interview selection cannot be explained by holistic review factors alone, and that the post-SFFA landscape requires institutions to eliminate racial preferences entirely, not merely to disguise them.

The absence of published details about the DOJ's statistical methodology makes independent evaluation difficult. Whether the analysis used logistic regression controlling for multiple variables, or a simpler comparison of candidates within similar academic bands, remains unclear from the publicly available documents.

The Diversity Stakes

The DOJ's enforcement campaign arrives at a moment when medical school diversity is already declining. According to AAMC data, in the first full admissions cycle after the SFFA ruling, the number of underrepresented-in-medicine (URiM) matriculants to MD programs fell sharply in fall 2024 compared to 2023 [10]:

• Black or African American: down 11.6%
• Hispanic or Latino: down 10.8%
• American Indian or Alaska Native: down 22.1%
• Native Hawaiian or Pacific Islander: down 4.3%

Source: AAMC

Data as of Oct 1, 2025CSV

These declines occurred despite increases in applicants from Black (up 2.8%) and Hispanic (up 2.2%) backgrounds, indicating that the drop was driven by lower acceptance rates, not reduced interest [10]. A cross-sectional study of 291,764 applicants to MD programs found an associated decline of 503 URiM matriculants in 2024 relative to the 2019–2023 period [4].

Research modeling race-blind admissions scenarios has projected that strict reliance on GPA and MCAT scores would leave only 3% of all medical students with underrepresented minority status — a reduction of roughly 70% from recent levels [11].

Does Physician Diversity Affect Patient Health?

Critics of the DOJ's enforcement posture argue that reducing physician diversity will worsen health outcomes, particularly for minority patients. The evidence on this point is growing but nuanced.

A study of 1.8 million Florida hospital births between 1992 and 2015 found that racial concordance between physicians and Black newborns was associated with significantly reduced infant mortality [12]. Separate research has linked same-race physician-patient relationships to improved preventive care, lower emergency department use among Asian and Hispanic patients, and lower total healthcare expenditures for Asian, Hispanic, and Black patients [13].

Academic interest in the topic has surged. Research publications on race concordance and physician health outcomes grew from 258 papers in 2011 to a peak of 1,573 in 2023, totaling over 10,800 papers in the period, according to OpenAlex data [14].

Source: OpenAlex

Data as of Jan 1, 2026CSV

However, the evidence base has limitations. The strongest findings concern patient satisfaction and communication quality; evidence linking concordance to measurable clinical outcomes beyond the neonatal mortality studies is thinner [13]. Some researchers have noted that findings are "inconclusive in determining an association between patient–provider concordance and patient outcomes" in many clinical domains [13].

The DOJ has directly addressed the concordance argument in its UCLA findings, stating that the school "adheres to the dubious contention that patients receive the best care when treated by a doctor of the same race, rather than by the most qualified" [2]. This framing presents the question as a binary choice between diversity and quality — a framing that many in academic medicine reject as a false dichotomy, since admitted URiM students at elite medical schools still meet high academic thresholds.

Alternative Paths to Diversity

The debate over race-conscious admissions has renewed interest in race-neutral strategies that have produced diverse classes at some institutions. UC Davis School of Medicine, operating under California's longstanding ban on racial preferences in public university admissions (Proposition 209, passed in 1996), enrolled one of the most diverse medical school classes in the country for the class of 2026, with nearly half the class from Black, Hispanic, and Indigenous backgrounds [15].

UC Davis achieved this through emphasis on recruiting "hometown" physicians from medically underserved areas, developing curricula focused on tribal medicine, rural medicine, and Central Valley agricultural communities, and weighting socioeconomic disadvantage in its admissions criteria [15]. Whether this model can scale to institutions like Yale — which draws from a national and international applicant pool and lacks UC Davis's geographic and mission-specific focus — remains an open question.

What Happens Next

The DOJ's letter to Yale seeks a "voluntary resolution agreement" to bring the school's admissions policies into compliance with Title VI [1][7]. If Yale declines to negotiate — or if negotiations fail — the DOJ has stated that it has the authority to file suit to enforce Title VI [7].

The potential consequences for Yale, should the DOJ ultimately prevail, are significant:

• Loss of federal funding: Title VI violations can result in termination of federal financial assistance. For a research-intensive medical school, this would mean loss of NIH grants, Medicare graduate medical education payments, and other federal support — a financially devastating outcome.
• Consent decree: A negotiated settlement could impose court-supervised monitoring of admissions practices for a period of years, with specific requirements around data reporting and methodology transparency.
• National precedent: A successful enforcement action against a school of Yale's stature would send a clear signal to every medical school receiving federal funds, accelerating the shift away from any admissions practices that produce racially disparate outcomes.

The timeline is uncertain. Voluntary negotiations could produce a resolution within months. Litigation, if it comes to that, could take years and would likely be appealed, potentially reaching the federal appellate courts.

The Bigger Picture

The DOJ's campaign against medical school admissions practices represents a test case for how far the federal government will go in enforcing the SFFA ruling. The Supreme Court banned the explicit use of race in admissions decisions, but left open whether institutions could consider race-adjacent factors — socioeconomic disadvantage, experiences with discrimination, community background — as part of holistic review.

The DOJ appears to be drawing that line aggressively, treating statistical disparities in admitted students' academic profiles as sufficient evidence of illegal race-consciousness, even without direct proof that admissions committees assigned points or preferences based on racial categories. If this evidentiary standard holds, it would effectively require medical schools to produce entering classes whose academic profiles show no significant variation across racial groups — a constraint that would fundamentally alter who gets into medical school in America.

Yale's response to the DOJ's findings will be closely watched. Whether the university chooses to negotiate, fight in court, or quietly adjust its practices will shape the legal landscape for medical education for years to come.